World's largest cosmetics ODM/OEM manufacturer, developing and producing skincare and makeup for global beauty brands.
World's largest cosmetics ODM/OEM manufacturer, developing and producing skincare and makeup for global beauty brands.
Develops formulas and manufactures finished beauty products for brands that sell them under their own labels, so it is paid per production order and for the formulations it creates for clients. It supplies both global groups and small independent brands, and runs plants in Korea, China, the US and Southeast Asia.
Moat: narrow (scale, process know-how). Largest global cosmetics contract manufacturer, embedded in many brands' product development.
Headquarters: Seoul, South Korea · Founded: 1992 · Employees: 1,565
Size Cosmax (192820.KS) is a South Korea Consumer Staples company (Household/Personal Care) with a market value of $2.51B, the 117th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩296,000 on 18 Nov 2026.
Performance Over six months the shares gained 52.7%, against +0.3% for the median peer and -37.2% for the South Korea market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 25.4% over the last twelve months (peer median +2.3%); the operating margin is 8.4% (peer median 10.9%).
Valuation It trades at 18.8× forward earnings against a peer median of 23.2× (8th cheapest of 21).
Capital Return on invested capital runs 5.1 points above its cost of capital (5.3% WACC).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩2.95T | ₩2.40T | ₩2.17T | ₩1.78T | ₩1.60T |
| Revenue growth | — | +11% | +22% | +11% | — |
| Gross profit | ₩487B | ₩395B | ₩405B | ₩368B | ₩270B |
| EBITDA | ₩331B | ₩270B | ₩238B | ₩174B | ₩111B |
| Net income | ₩218B | ₩123B | ₩85.8B | ₩57.1B | ₩20.8B |
| Free cash flow | -₩155B | -₩100B | -₩58.2B | ₩145B | ₩18.4B |
| Capital expenditure | ₩308B | ₩193B | ₩169B | ₩90.6B | ₩84.4B |
| Total debt | ₩1.23T | ₩825B | ₩821B | ₩656B | ₩608B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Cosmax 192820.KS | $2.51B | +53% | +25% | 8% | 18.8× | n/a |
| Kolmar Korea 161890.KS | $2.05B | +14% | +16% | 10% | 14.3× | -1.6% |
| Cosmecca Korea 241710.KS | $847M | +23% | +42% | 12% | 16.3× | n/a |
| Intercos ICOS.MI | $1.43B | +12% | -5% | 9% | 18.9× | 4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 192820.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.4% | +2.2% | 8th highest of 21 |
| 6-month return | +52.7% | +0.3% | 4th highest of 21 |
| Distance from 52-week high | -7.5% | -22.4% | 9th highest of 21 |
| Revenue growth (TTM) | +25.4% | +2.3% | highest of 21 |
| Operating margin | 8.4% | 10.9% | 7th lowest of 21 |
| Forward P/E | 18.8× | 23.2× | 8th cheapest of 21 |
| ROIC minus cost of capital | +5.1 pp | +5.4 pp | 10th lowest of 20 |
| EV / EBITDA | 13.3× | 10.3× | 6th most expensive of 17 |
| Net debt / EBITDA | 3.0× | -0.8× | 3rd most indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cosmax 192820.KS | South Korea | $2.51B | +53% | +25% | 8% | 18.8× | n/a | n/a |
| Winner Medical 300888.SZ | China | $2.53B | -6% | +4% | 11% | 19.9× | -5.2% | -2.6% |
| Gillette India GILLETTE.NS | India | $2.53B | -5% | +8% | 28% | 37.1× | 14.9% | +13.0% |
| Giant Biogene 2367.HK | Hong Kong | $2.47B | -32% | -10% | 32% | 8.6× | -10.7% | +34.9% |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.37B | -30% | -2% | 24% | 27.0× | 21.2% | +7.4% |
| LG H&h 051900.KS | South Korea | $2.81B | -14% | -3% | 3% | 23.1× | -4.6% | -4.1% |
| Softcare 2698.HK | Hong Kong | $2.20B | +5% | +25% | 25% | 14.4× | 9.1% | +20.9% |
| Proya Cosmetics 603605.SS | China | $2.87B | -13% | +2% | 13% | 10.9× | -5.3% | +23.1% |
| KOSE 4922.T | Japan | $2.16B | +16% | +4% | 5% | 29.9× | n/a | n/a |
| Blue Moon 6993.HK | Hong Kong | $2.07B | -4% | -2% | -2% | 103.3× | n/a | n/a |
| Kolmar Korea 161890.KS | South Korea | $2.05B | +14% | +16% | 10% | 14.3× | -1.6% | +15.5% |
| Pola Orbis 4927.T | Japan | $2.04B | +15% | +1% | 11% | 30.6× | -2.0% | -0.7% |
| Emami EMAMILTD.NS | India | $1.94B | -5% | +13% | 20% | 23.4× | 21.5% | +5.6% |
| Energizer ENR | United States | $1.94B | +71% | 0% | 17% | 9.1× | -5.1% | -0.5% |
| Kobayashi Pharmaceutical 4967.T | Japan | $3.25B | +20% | +2% | 6% | 48.7× | 18.0% | +1.9% |
| Hengan Int'l 1044.HK | Hong Kong | $3.27B | -12% | +2% | 11% | 9.1× | -8.2% | -0.1% |
| Interparfums ITP.PA | France | $3.49B | +66% | -4% | 18% | 26.9× | 15.6% | +19.6% |
| Pigeon 7956.T | Japan | $1.76B | +26% | +8% | 13% | 27.9× | -2.4% | +1.9% |
| Coty COTY | United States | $3.71B | +116% | 0% | 5% | 13.5× | 9.8% | +4.6% |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.69B | -33% | +7% | 9% | 19.1× | 2.6% | +15.3% |
| Lion 4912.T | Japan | $3.85B | +44% | +6% | 8% | 24.3× | 0.9% | +3.5% |